A citation-based method for searching scientific literature

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Times Cited: 156



Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
Times Cited: 95




List of shared articles



Times cited

The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
Saniya Tandon, Salma Ayis, David Hopkins, Seeromanie Harding, Marietta Stadler. Diabetes Obes Metab 2021
3

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Moshe Phillip, Chantal Mathieu, Marcus Lind, Eiichi Araki, Paolo di Bartolo, Richard Bergenstal, Simon Heller, Lars Hansen, Markus Florian Scheerer, Fredrik Thoren,[...]. Diabetes Obes Metab 2021
6


Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hailan Zou, Lili Liu, Jia Guo, Hongjuan Wang, Siyun Liu, Yixuan Xing, Chao Deng, Yang Xiao, Zhiguang Zhou. J Diabetes Investig 2021
2


The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.
Józef Drzewoski, Markolf Hanefeld. Pharmaceuticals (Basel) 2021
6

Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Eiichi Araki, Chantal Mathieu, Toshihiko Shiraiwa, Hajime Maeda, Hiroki Ikeda, Fredrik Thoren, Niki Arya, Michiko Asano, Nayyar Iqbal. Diabetes Obes Metab 2021
2



A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.
Curtis K Johnston, Rena J Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M Riggs, Karl-Heinz Liesenfeld. Pharmaceutics 2021
0

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
David Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal. Diabetes Obes Metab 2021
0

Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Lian A van Meijel, Cees J Tack, Bastiaan E de Galan. Diabetes Obes Metab 2021
0


Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.
Melissa-Rosina Pasqua, Michael A Tsoukas, Ahmad Haidar. J Diabetes Sci Technol 2021
0

The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
A Gal, S E Burton, K Weidgraaf, P Singh, N Lopez-Villalobos, A Jacob, U Malabu, R Burchell. Domest Anim Endocrinol 2020
0


Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
13

Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge.
C David Mazer, Amel Arnaout, Kim A Connelly, Jeremy D Gilbert, Stephen A Glazer, Subodh Verma, Ronald M Goldenberg. Curr Opin Cardiol 2020
1

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
15

Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme.
Jason Gordon, Lee Beresford-Hulme, Hayley Bennett, Amarjeet Tank, Christopher Edmonds, Phil McEwan. Diabetes Obes Metab 2020
3



Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
Hayley Bennett, Amarjeet Tank, Marc Evans, Klas Bergenheim, Phil McEwan. Diabetes Obes Metab 2020
3

Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice.
Kana N Miyata, Shuiling Zhao, Chin-Han Wu, Chao-Sheng Lo, Anindya Ghosh, Isabelle Chenier, Janos G Filep, Julie R Ingelfinger, Shao-Ling Zhang, John S D Chan. Diabetes Res Clin Pract 2020
4

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
Jason Gordon, Thomas Danne, Lee Beresford-Hulme, Hayley Bennet, Amarjeet Tank, Christopher Edmonds, Fredrik Thorén, Markus Florian Scheerer, Phil McEwan. Diabetes Ther 2020
1

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
14

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.
Chantal Mathieu, Paresh Dandona, Andreas L Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, John Xu, Enrico Repetto, Markus Florian Scheerer, Fredrik Thoren, Moshe Phillip. Diabetes Obes Metab 2020
5

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
2


SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu. Ther Adv Endocrinol Metab 2020
4

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Per-Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven Edelman, Johan Jendle, John Xu, Markus F Scheerer, Fredrik Thoren, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2020
8

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes.
Pieter Gillard, Oliver Schnell, Per-Henrik Groop. Diabetes Res Clin Pract 2020
2


An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Georgios Chatzopoulos, Konstantinos Tziomalos. Expert Opin Pharmacother 2020
1


Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Hirotaka Watada, Masanari Shiramoto, Shinya Ueda, Weifeng Tang, Michiko Asano, Fredrik Thorén, Hyosung Kim, Toshitaka Yajima, David W Boulton, Eiichi Araki. Diabetes Obes Metab 2019
11

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
106

Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2019
26


Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
5


Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.
Amber L Beitelshees, Bruce R Leslie, Simeon I Taylor. Diabetes 2019
15

SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution.
Joseph I Wolfsdorf, Robert E Ratner. Diabetes Care 2019
11

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George,[...]. Diabetes Care 2019
5